Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
Lauren White has been appointed as Chief Financial Officer of Seaport Therapeutics, a clinical-stage biopharmaceutical company focused on neuropsychiatric medicines. White previously served as CFO at ImmunoGen, where she played a important role in the company's $10.1 billion acquisition by AbbVie in 2024 and the commercial launch of ELAHERE®. With over 22 years of experience, White's background includes positions at C4 Therapeutics, Novartis, Boston Consulting Group, and General Electric. She holds a BS from Boston College and an MBA from Harvard Business School.
AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics announced a collaboration and option-to-license agreement to develop multispecific biologics for cancer treatment. The partnership combines AbbVie's oncology expertise with EvolveImmune's proprietary EVOLVE T-Cell Engager Platform, designed to deliver potent T-cell co-stimulation to enhance tumor-killing capacity.
The agreement includes $65 million in upfront fees and equity investment from AbbVie, with potential earnings of up to $1.4 billion in option fees and milestones, plus tiered royalties on net sales. The platform aims to overcome therapeutic challenges in solid and hematologic tumors by bypassing low tumor immunogenicity and reducing T-cell dysfunction.
AbbVie (ABBV) reported strong Q3 2024 financial results with worldwide net revenues of $14.460 billion, up 3.8% on a reported basis. The company's immunology portfolio generated $7.046 billion, while neuroscience portfolio reached $2.363 billion. Adjusted diluted EPS was $3.00, including a $0.04 per share impact from IPR&D expenses. AbbVie raised its 2024 adjusted EPS guidance to $10.90-$10.94 and announced a 5.8% dividend increase for 2025. The company successfully completed the Cerevel acquisition, strengthening its neuroscience portfolio.
SkinSpirit is partnering with Allergan Aesthetics, an AbbVie company, to support Girls Inc. in promoting STEM careers among young women. SkinSpirit will initiate the campaign with a $5,000 donation through SkinSpirit Gives and enable client donations from November 1-15th, with all proceeds supporting Girls Inc.'s STEM programming across 350 cities and 75 affiliates nationwide, reaching over 114,000 girls. This marks the sixth year of Allergan Aesthetics' partnership with Girls Inc. and SkinSpirit's first year of participation in the initiative.
AbbVie (NYSE: ABBV) has announced the acquisition of Aliada Therapeutics for $1.4 billion in cash, strengthening its neuroscience pipeline. The deal centers on Aliada's lead compound ALIA-1758, an anti-pyroglutamate amyloid beta antibody in development for Alzheimer's disease, currently in Phase 1 trials. The acquisition includes Aliada's proprietary MODEL™ platform, featuring novel blood-brain barrier crossing technology that targets transferrin and CD98 receptors for enhanced CNS drug delivery. The transaction is expected to close in Q4 2024, subject to regulatory approvals.
AbbVie and Gedeon Richter have announced a new discovery, co-development and license agreement for novel neuropsychiatric treatments. The collaboration expands their nearly two-decade partnership in CNS projects. Under the agreement terms, Richter will receive a $25 million upfront payment plus potential future milestones and sales-based royalties. AbbVie gains worldwide commercialization rights except for Richter's traditional markets including Europe, Russia, CIS countries, and Vietnam. The partnership builds on previous successes including cariprazine and investigational drug ABBV-932 for bipolar depression and anxiety disorder.
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced FDA approval of BOTOX® Cosmetic for temporary improvement of moderate to severe platysma bands in adults. This marks BOTOX® Cosmetic's fourth aesthetic indication, making it the first product to go beyond the face. The approval offers a nonsurgical, injectable option for treating vertical bands connecting the jaw and neck.
In Phase III clinical studies, BOTOX® Cosmetic demonstrated significant improvement in platysma band appearance compared to placebo. The FDA-approved doses are 26, 31, or 36 units based on severity. A majority of patients reported being satisfied with their neck and jawline definition after treatment.
Patients can learn more and enroll in Allē, Allergan Aesthetics' loyalty rewards program, which offers points on various treatments and flexible payment options.
AbbVie announced that the U.S. FDA has approved VYALEV™ (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for treating motor fluctuations in adults with advanced Parkinson's disease (PD). The approval was based on a 12-week Phase 3 study and a 52-week open-label study. Key findings include:
1. VYALEV demonstrated superior improvement in motor fluctuations compared to oral immediate-release carbidopa/levodopa.
2. Patients reported increased "on" time without troublesome dyskinesia and decreased "off" time.
3. Most adverse reactions were non-serious and mild to moderate in severity.
4. The most frequent adverse reactions were infusion site events, hallucinations, and dyskinesia.
VYALEV allows for personalized dosing based on individual needs. Coverage for Medicare patients is expected in the second half of 2025.
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), will present data at the 2024 American Society for Dermatologic Surgery (ASDS) Annual Meeting, showcasing efficacy, safety, and patient-reported outcomes across its facial injectable portfolio. The company will present 12 abstracts, including four Best of Cosmetic Abstracts, demonstrating its commitment to patient outcomes and understanding key concerns across patient segments.
Highlights include:
- Safety and patient-reported outcomes for BOTOX® Cosmetic in treating platysma bands
- Patient satisfaction with JUVEDERM VOLUMA XC for temple hollowing
- Findings from a 4,000-subject study across ethnic, racial, and gender groups
Allergan Aesthetics will also host a panel discussion on social integrity in the aesthetics industry, focusing on social media trends and ethical practices. The event will take place on October 17-20, 2024, in Orlando, Florida.
Allergan Aesthetics, an AbbVie company, announces its sixth consecutive year of partnership with Girls Inc. to support high school and college girls' interest in STEM and mentorship. The collaboration aims to highlight the importance of mentorship and role models in addressing challenges and supporting women and girls in STEM careers.
The partnership includes programs like "Girls Meet the Workforce" with the Orange County Girls Inc. affiliate, mentoring nearly 100 girls in four years. Allergan Aesthetics is launching an online social campaign from October 4th to November 8th, 2024, encouraging aesthetics professionals and consumers to take a mentorship moment with a girl in their lives.
At the Girls Inc. Be Bold LeadHERS Summit at Houston Community College, participants will engage with successful women physician role models in Houston during the Empower YOU panel. The initiative aims to increase education, improve confidence, and expand networks for girls pursuing STEM careers.